SCHEMBL6138470

SCHEMBL6138470

COC(=O)c1ccc(-c2cccc(C)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.60
TDP1 Q9NUW8 1/20 0.58
MAPK14 Q16539 1/20 0.55
HSD17B2 P37059 2/20 0.55
HSD17B1 P14061 1/20 0.55
MAPT P10636 2/20 0.54
POLB P06746 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
CA12 O43570 3/20 0.54
CA1 P00915 3/20 0.54
CA2 P00918 3/20 0.54
CA9 Q16790 3/20 0.54
ERN1 O75460 2/20 0.53
PLAU P00749 2/20 0.52
SLC2A1 P11166 1/20 0.51
HSD17B10 Q99714 2/20 0.50
CA14 Q9ULX7 2/20 0.50
TSHR P16473 1/20 0.50
PTPN1 P18031 1/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31298127 1.00 EGFR (0.60) EGFRTDP1MAPK14HSD17B2HSD17B1
SCHEMBL28189889 0.89 EGFR (0.68) EGFRTDP1CA12CA1CA2
SCHEMBL30285148 0.88 CA12 (0.59) CA12CA1CA2CA9ERN1
SCHEMBL7719381 0.88 CA12 (0.59) CA12CA1CA2CA9ERN1
SCHEMBL27589486 0.87 TSHR (0.64) EGFRTDP1MAPTCA12CA1
SCHEMBL68931 0.86 CA12 (0.69) EGFRCA12CA1CA2CA9
SCHEMBL4146997 0.83 TDP1 (0.61) TDP1HSD17B2HSD17B1MAPTCA12
SCHEMBL514 0.83 CA12 (0.66) EGFRTDP1CA12CA1CA2
SCHEMBL31337006 0.83 EGFR (0.65) EGFRHSD17B2HSD17B1CA12CA1
SCHEMBL4700092 0.83 EGFR (0.65) EGFRHSD17B2HSD17B1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176777-A Cyclic alpha-hydroxyimide compound and application thereof 北京英飞智药科技有限公司 2024-12-24 CN disclosed
CN-109311813-B Palladium-catalyzed meta-C-H functionalized universal ligands 斯克利普斯研究院 2023-02-28 CN disclosed
US-11485721-B2 Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (DE) 2022-11-01 US disclosed
EP-3885343-A1 INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2021-09-29 EP disclosed
US-20200339529-A1 METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) 2020-10-29 US disclosed
US-20200338074-A1 COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-10-29 US disclosed
US-10781183-B2 Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-09-22 US disclosed
US-20190308942-A1 SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-10-10 US disclosed
US-20190211045-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS UNIV WASHINGTON (US) 2019-07-11 US disclosed
WO-2019101679-A1 METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL INSTITUT (HKI) (DE) 2019-05-31 WO disclosed
US-20150197538-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-07-16 US disclosed
US-8937167-B2 Compounds and methods for treating bacterial infections WASHINGTON UNIVERSITY (US) 2015-01-20 US disclosed
US-8937167-B2 Compounds and methods for treating bacterial infections WASHINGTON UNIVERSITY (US) 2015-01-20 US disclosed
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS THE WASHINGTON UNIVERSITY (US) 2012-12-06 US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 EP disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
EP-1313560-A4 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION UNIV YALE (US) 2005-02-09 EP disclosed
EP-1313560-A1 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION YALE UNIVERSITY (US) 2003-05-28 EP disclosed
WO-2002011883-A1 CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION YALE UNIVERSITY (US) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308942-A1 SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY SQOR, MAVS, TFAM EGFR 1693/4885TDP1 2586/4885MAPK14 1255/4885
US-20120309701-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS MMP8, ELANE, GUSB EGFR 2365/4885TDP1 4366/4885MAPK14 4209/4885
US-11485721-B2 Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses CBR3, POR, CYP2F1 EGFR 3202/4885TDP1 4859/4885MAPK14 3698/4885
US-20200339529-A1 METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES CBR3, POR, CYP2F1 EGFR 3202/4885TDP1 4859/4885MAPK14 3698/4885
US-20190211045-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS MMP8, ELANE, GUSB EGFR 2365/4885TDP1 4366/4885MAPK14 4209/4885
US-10781183-B2 Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity SQOR, MAVS, TFAM EGFR 1693/4885TDP1 2586/4885MAPK14 1255/4885
US-20150197538-A1 COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS MMP8, ELANE, GUSB EGFR 2365/4885TDP1 4366/4885MAPK14 4209/4885
US-20200338074-A1 COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS CHUK, BCOR, MYC EGFR 658/4885TDP1 662/4885MAPK14 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.